1609259-60-0

Usage

Uses

Used in Pharmaceutical Industry:
6-amino-1,5-dimethylpyrimidine-2,4(1H,3H)-dione is used as a synthetic intermediate for the production of T791550, a compound with potential applications in the pharmaceutical industry. T791550 is synthesized from 6-amino-1,5-dimethylpyrimidine-2,4(1H,3H)-dione hydrochloride, and its development is focused on creating new drugs with improved therapeutic properties.
Used in Chemical Synthesis:
In the field of chemical synthesis, 6-amino-1,5-dimethylpyrimidine-2,4(1H,3H)-dione is utilized as a key component in the creation of various complex molecules. Its unique structure allows for further functionalization and modification, making it a valuable asset in the development of new compounds with diverse applications, such as pharmaceuticals, agrochemicals, and other specialty chemicals.
Used in Research and Development:
6-amino-1,5-dimethylpyrimidine-2,4(1H,3H)-dione is also employed in research and development laboratories, where it is used to study the properties and reactivity of pyrimidine-based compounds. This knowledge can be applied to the design and synthesis of novel molecules with specific biological activities, contributing to the advancement of various scientific fields.

Upstream product

• 1572-99-2 ethyl 2-cyanopropionate 
• 598-50-5 N-Methylurea 

Downstream Products

• 1609259-61-1 6-bromo-1,5-dimethylpyrimidine-2,4(1H,3H)-dione 
• 1609259-62-2 6-bromo-3-(3,4-dimethoxybenzyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione 
• 1609259-63-3 3-(3,4-dimethoxybenzyl)-6-(4-hydroxy-2-methylphenyl)-1,5-dimethylpyrimidine-2,4(1H,3H)-dione 
• 1643489-24-0 (-)-1,5-dimethyl-6-(2-methyl-4-([3-(trifluoromethyl)pyridin-2-yl]oxy)phenyl)pyrimidine-2,4(1H,3H)-dione 
• 1643489-24-0 (+)-1,5-dimethyl-6-(2-methyl-4-([3-(trifluoromethyl)pyridin-2-yl]oxy)phenyl)pyrimidine-2,4(1H,3H)-dione 
• 1643489-24-0 1,5-dimethyl-6-(2-methyl-4-((3-(trifluoromethyl)pyridin-2-yl)-oxy)phenyl)pyrimidine-2,4(1H,3H)-dione 

Relevant academic research and scientific papers

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula (I): and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1-mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), schizotypal personality disorder, cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, Parkinson's disease, anxiety, and depression.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides of the foregoing; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds, salts or N-oxides, and their uses for treating D1-mediated (or D1-associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), ADHD, impulsivity, compulsive gambling, overeating, autism spectrum disorder, MCI, age-related cognitive decline, dementia, RLS, Parkinson's disease, Huntington's chorea, anxiety, depression, MDD, TRD, and bipolar disorder.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula I: and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced β- arrestin recruitment activity relative to Dopamine, D1 agonists interacting significantly with the Ser188 but not significantly with the Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with the Asp103 and interacting less strongly with the Ser198 of a D1R when binding to the D1R, and their uses.

HETEROAROMATIC COMPOUNDS AND THEIR USE AS DOPAMINE D1 LIGANDS

The present invention provides, in part, compounds of Formula (I) and pharmaceutically acceptable salts thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds or salts, and their uses for treating D1 -mediated (or D1 -associated) disorders including, e.g., schizophrenia (e.g., its cognitive and negative symptoms), cognitive impairment (e.g., cognitive impairment associated with schizophrenia, AD, PD, or pharmacotherapy therapy), age-related cognitive decline, dementia, and Parkinson's disease.